Novartis, the on-demand biotech company, has been under prominent financial observation recently. The pharmaceutical pioneer has seen an increase in stock holdings by Balyasny Asset Management L.P. and also witnessed a recent stock upgrade from 'Neutral' to 'Overweight' by eminent financial institution,
JPMorgan. Although challenged by generics denting their blockbuster heart drug, the company's worth rose due to late-stage pipeline wins and their innovative deal with AI Drug Discovery. A plunge of $1.7 billion for an AI Allergy Breakthrough and the acquisition of U.S. biotech firm
Avidity Biosciences for approximately $12 billion has also spurred conversations about the company's future valuation. On the flipside,
Goldman Sachs suggested the stock might be overvalued after hitting a 52-week high and Dearborn Partners sold 26,963 Novartis shares, causing a minor setback. In the face of these financial movements, the Swiss pharmaceutical titan continues to strengthen with full-year guidance reflecting Avidity acquisition and portfolio growth. Regulatory approvals and product launches, notably being FDA's approval of the first gene therapy for muscle-weakening disorder, is also driving the value of Novartis shares. Not all reviews have been positive, with Novartis downgraded to ‘Sell’ by Goldman Sachs on growth concerns amid a CEO transition.
Novartis Stocks News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 13 Dec 2025 08:54:37 GMT -
Rating 7
- Innovation 5
- Information 6
- Rumor -6
